HC Wainwright Reiterates “Buy” Rating for CalciMedica (NASDAQ:CALC)

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $16.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 370.59% from the company’s current price.

CalciMedica Stock Down 2.6 %

Shares of NASDAQ CALC opened at $3.40 on Thursday. The stock has a market capitalization of $36.55 million, a PE ratio of -2.43 and a beta of 1.30. The firm has a fifty day moving average of $4.12 and a 200-day moving average of $4.56. CalciMedica has a 52-week low of $2.68 and a 52-week high of $8.38.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. Equities research analysts expect that CalciMedica will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Robert N. Wilson purchased 54,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average cost of $3.72 per share, with a total value of $200,880.00. Following the transaction, the director now owns 364,196 shares in the company, valued at approximately $1,354,809.12. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other CalciMedica news, Director Robert N. Wilson bought 54,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $3.72 per share, with a total value of $200,880.00. Following the transaction, the director now directly owns 364,196 shares in the company, valued at approximately $1,354,809.12. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were bought at an average cost of $3.75 per share, with a total value of $325,751.25. Following the transaction, the insider now directly owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 312,944 shares of company stock valued at $1,172,910 over the last ninety days. Corporate insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc grew its position in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the quarter. Atria Investments Inc owned approximately 0.25% of CalciMedica worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.